To determine whether their inhibition would be useful for primary brain tumors that may have different mutation profiles, we selected two primary GBM-derived cell lines having similar HSP27 and SPARC expression profiles, but which differed in their PTEN, MGMT, and p53 status (see Additional file 4: Table S1). This evidence concerns the gene MGMT and brain neoplasm.